Wessex Neurological Centre, Southampton, United Kingdom.
Royal Hallamshire Hospital, Sheffield, United Kingdom.
World Neurosurg. 2020 Sep;141:406-412. doi: 10.1016/j.wneu.2020.04.224. Epub 2020 May 8.
Masson tumor or intravascular papillary endothelial cell proliferation was first described in 1923. Only a few cases of intracranial Masson tumor have been reported following stereotactic radiosurgery (SRS). We report a series of 6 cases, age range 28-56 years, with intracranial Masson tumor following SRS for treatment of an intracranial arteriovenous malformation (AVM).
We performed a retrospective case note review, reviewed the imaging, SRS records, and neuropathology specimens following surgical excision.
In our series all patients received Leksell SRS with the periphery of the AVM receiving doses ranging from 22-25 Gy. The time lapse from SRS to a clear enhancing mass appearing on imaging ranged from 5-10 years. Four patients underwent craniotomy and excision of the enhancing lesion for persistent edema and an enlarging cyst resulting in a resolution of symptoms.
SRS is an effective treatment for obliteration of intracranial AVMs.
Masson 肿瘤或血管内乳头状内皮细胞增生于 1923 年首次被描述。仅报道了少数几例立体定向放射外科治疗（SRS）后颅内 Masson 肿瘤的病例。我们报告了一组 6 例患者，年龄 28-56 岁，因颅内动静脉畸形（AVM）接受 SRS 治疗后出现颅内 Masson 肿瘤。
我们进行了回顾性病历审查，回顾了影像学、SRS 记录和手术切除后的神经病理学标本。
在我们的系列中，所有患者均接受了 Leksell SRS 治疗，AVM 周边接受的剂量范围为 22-25Gy。从 SRS 到影像学上出现明显增强肿块的时间间隔为 5-10 年。4 名患者因持续水肿和增大的囊肿导致症状加重而行开颅切除术和增强病变切除术。
SRS 是治疗颅内 AVM 闭塞的有效方法。
